Connect with us

Technology

Nanoscope Therapeutics Appoints Gene Therapy Operations Leader Troy Short as Senior Vice President, Manufacturing and Supply Chain

Published

3 hours ago

on

Operations and supply chain executive with more than 20 years of experience spanning GMP manufacturing, global clinical and commercial supply, and gene therapy launch executionFormer VP of Global Supply Chain and interim Chief Technical Officer at AveXis, where he built and led the global supply chain organization through the launch of Zolgensma® across more than 30 countriesAppointment strengthens manufacturing and supply chain leadership as Nanoscope advances lead product MOGENRY™ through regulatory review toward potential global commercialization

DALLAS, Oct. 14, 2026 /PRNewswire/ — Nanoscope Therapeutics Inc., a biotechnology company committed to developing and commercializing novel, disease-agnostic therapies for patients with photoreceptor loss and vision impairment due to retinal degeneration, today announced the appointment of Troy Short as Senior Vice President, Manufacturing and Supply Chain. In this role, Short will lead Nanoscope’s GMP manufacturing, commercial supply, and global distribution strategy as the company advances toward the potential approval and launch of MOGENRY™ (sonpiretigene isteparvovec; MCO-010).

Mr. Short brings more than two decades of operations and supply chain leadership across the pharmaceutical and gene therapy industries, with particular depth in building the manufacturing and distribution capabilities required to bring genetic medicines to patients. He previously served as Vice President of Global Supply Chain at AveXis, Inc., where he built and led the global commercial supply chain organization through the launch of Zolgensma®, scaling distribution globally, including the design of the specialized cold-chain model required for patient-specific delivery. He negotiated supply agreements, managed raw material sourcing, led the enterprise resource planning system implementation, and played a leadership role in FDA licensure and commercial readiness. Following the acquisition of AveXis by Novartis, he served as interim Chief Technical Officer during the transition.

Mr. Short subsequently served as Senior Vice President of Manufacturing and Supply Chain at Jaguar Gene Therapy, where he built Jaguar’s CMC and supply chain organization, internalized process and analytical development, and directed the design of their GMP manufacturing facility. He later served as Chief Operating Officer of Advanced Medicine Partners, leading the design and startup of their GMP facility. Most recently, through his firm GTxConsulting, he has advised biotechnology companies and investment firms on CMC strategy, as well as supply chain and BLA readiness for gene therapies and other advanced modalities. Earlier in his career, Mr. Short spent 11 years at Hospira, a Pfizer company, as Director of Supply Chain for sterile pharmaceutical manufacturing.

“Troy has done what very few people in our industry have done: built and run the supply chain that delivered an approved AAV gene therapy to patients around the world,” said Sulagna Bhattacharya, Co-Founder and Chief Executive Officer of Nanoscope Therapeutics. “A one-time intravitreal therapy manufactured in the U.S. has to reach every patient who needs it, at quality, without interruption. That capability is built years in advance, and Troy knows exactly how to execute. His arrival at this stage reflects how seriously we are taking our preparation for launch.”

Nanoscope continues to build clinical, regulatory, scaled-up manufacturing, and commercial-preparation momentum in support of MOGENRY for inherited retinal dystrophies (IRDs). The U.S. Food and Drug Administration (FDA) has accepted and filed the company’s Biologics License Application (BLA) for MOGENRY for the treatment of retinitis pigmentosa (RP) with severe vision loss. The BLA is presently under FDA review. A Japan New Drug Application (JNDA) for MOGENRY is also currently under PMDA review for IRDs. These milestones reflect the company’s expanding international regulatory pathway as it advances commercialization planning across key global markets.

“MOGENRY is designed to work regardless of the gene behind a patient’s vision loss. My job is to make sure it reaches them,” said Short. “My focus will be on strengthening our manufacturing partnerships, building a resilient commercial supply chain, and making sure patients and their physicians can count on product availability upon its potential approval.” 

About Inherited Retinal Dystrophies
Inherited retinal dystrophies (IRDs) are a genetically diverse group of rare disorders, caused by mutations in more than 250 genes, in which progressive loss of photoreceptor cells leads to impaired vision and, in most cases, complete blindness. IRDs include retinitis pigmentosa, the most common IRD, as well as Stargardt disease, cone-rod dystrophies, and Leber congenital amaurosis, among others. Because gene-specific therapies address only a single genetic cause, the vast majority of patients with IRDs have no approved treatment option.

About MOGENRY (sonpiretigene isteparvovec; MCO-010)
Nanoscope’s multi-characteristic opsin (MCO) technology utilizes a proprietary genetically engineered synthetic opsin to enable optimized performance in terms of high light sensitivity across a broad spectrum and fast kinetics. After Nanoscope’s Co-Founder, President, and Chief Scientific Officer, Samarendra Mohanty, envisioned and invented the technology, his team spent more than a decade evaluating its performance across multiple animal models and human diseases. MOGENRY is an investigational, one-time, in-office, intravitreal optogenetic gene therapy built on Nanoscope’s MCO platform. By delivering a multi-characteristic opsin gene to the highly dense bipolar retinal cells, MOGENRY makes these surviving cells directly light-sensitive, enabling them to utilize the remaining visual circuitry following photoreceptor loss. MOGENRY does not require genetic testing, invasive surgery, or repeat dosing, and is designed for administration within existing retina office workflows.

About Nanoscope Therapeutics
Nanoscope Therapeutics is developing disease-agnostic, vision-restoring optogenetic therapy for millions of patients blinded by retinal degenerative diseases. Following positive results from the RESTORE Phase 2b/3 multicenter, randomized, double-masked, sham-controlled clinical trial for RP (NCT04945772), the FDA has accepted and filed the company’s BLA for MOGENRY, and the PMDA has accepted for priority review the company’s Japan new drug application (JNDA) for MOGENRY for the treatment of IRDs. If approved, MOGENRY has the potential to become the standard of care for patients with RP and other IRDs, administered as a one-time, in-office injection without the need for genetic testing. The company has also shown promising results in the STARLIGHT Phase 2 clinical trial (NCT05417126) of MCO-010 in Stargardt disease (SD) and plans to initiate a Phase 3 registrational trial in 2026. MCO-010 has received FDA Fast Track and Orphan Drug designations for both RP and SD, along with Regenerative Medicine Advanced Therapy (RMAT) designation for SD, and European Medicines Agency (EMA) Orphan designations covering non-syndromic and syndromic rod- and cone-dominant dystrophies, as well as macular dystrophies. MCO-010 has also received Sakigake and Orphan designations for IRDs in Japan and an Orphan designation for IRDs in Saudi Arabia. A Phase 2 program for MCO in geographic atrophy is expected to start in 2026, and other investigational new drug (IND)-ready programs include Leber congenital amaurosis (LCA). Learn more at NanosTherapeutics.com and follow @NSTherapeutics on X and on LinkedIn. 

Contact:
Nanoscope Therapeutics Inc.
+1 (817) 857-1186
PR@nanostherapeutics.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/nanoscope-therapeutics-appoints-gene-therapy-operations-leader-troy-short-as-senior-vice-president-manufacturing-and-supply-chain-302908069.html

SOURCE Nanoscope Therapeutics

Related Topics:
Continue Reading

Technology

Omega Point’s MCP Is Now Anthropic Verified in Claude’s Marketplace, Built To Compute

Published

38 minutes ago

on

October 14, 2026

By

Reviewed by Anthropic for quality and security, built on investment intelligence trusted for over a decade

NEW YORK, Oct. 14, 2026 /PRNewswire/ — Omega Point’s MCP has been in production and used by investment teams in Claude since May. Now, Omega Point’s MCP is Anthropic-verified. Every connector in Claude’s marketplace passes an automated check. “Verified” status goes further: Anthropic evaluated Omega Point directly for quality and security before clearing it for Claude, the foundation for a seamless experience inside Claude. 

Most connectors just display what’s already there. Omega Point’s MCP computes the answer from a team’s own positions, their own mandates, their own data, their world, not a generic read on the market. It’s the same engine the world’s largest investors have trusted for over a decade. The result isn’t a report pulled off a shelf. It’s built fresh, from their book, every time.

In practice:

Ask anything, not just what’s on a screen. Factor risk by sector over time for one sleeve, or the names driving 10% of risk and their month-to-date P&L. Claude builds the answer directly from Omega Point’s Intelligence Engine, scoped to what that user is already cleared to see.Test before you trade. Paste a trade list and see the before-and-after risk, exposures, and stress in one pass, or load a full book from a file instead of entering positions one at a time.Numbers that match your risk report. What-ifs, stress tests, and attribution come from the same models and engine behind the firm’s official numbers, not a separate approximation.

Teams can also bring their own research and signals into the same analysis, so everyone is working from one shared source of truth instead of reconciling spreadsheets.

“For years, software made you adopt its worldview just to get an answer. Claude flips that. The analytics and workflows are the same deterministic engine investors have trusted for over a decade, but now they show up inside your own context and conviction. The software adapts to you, not the other way around,” said Omer Cedar, Founder and CEO of Omega Point.

Omega Point is available now, verified, in Claude’s marketplace at https://claude.ai/directory/omega-point.

About Omega Point
Omega Point is the AI-native investment intelligence platform for hedge funds, asset managers, and allocators, turning all your investment data into decisions through institutional risk, performance, thematic, and factor analytics and workflows. Built for every role across the front office.

Media Contact

Joel Coverdale, Managing Director, Investment Solutions
+1-332-286-3900
424683@email4pr.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/omega-points-mcp-is-now-anthropic-verified-in-claudes-marketplace-built-to-compute-302908021.html

SOURCE Omega Point

Continue Reading

Technology

Mindtrip Partners with Norwegian Travel Cluster to Power AI-Driven Discovery Across Norway’s 29 Destination Regions

Published

39 minutes ago

on

October 14, 2026

By

Partnership which marks Mindtrip’s first launch in Europe, brings conversational AI trip planning to the Norwegian Travel Cluster’s “Norway by Locals” platform, connecting travelers with authentic experiences across 150+ municipalities, and thousands of tourism businesses nationwide

SAN FRANCISCO, Oct. 14, 2026 /PRNewswire/ — Mindtrip, an AI-powered travel platform that empowers people to travel differently, today announced a strategic partnership with the Norwegian Travel Cluster, marking the company’s first destination partnership in Europe and first launch in Scandinavia.

The collaboration will introduce Mindtrip’s travel discovery experience as a core feature of the upcoming “Norway by Locals” website, a national travel planning platform created by Norwegian destination organizations and powered by Mindtrip. A first-of-its-kind initiative uniting all 29 destination organizations within the Norwegian Travel Cluster, the platform combines trusted local knowledge with AI to help travelers turn inspiration into practical, personalized trips. Drawing on content from destination websites and selected local partner listings, Norway by Locals makes it easy for visitors to discover, plan, save, and share journeys across multiple Norwegian destinations.

“AI is transforming how people discover and plan travel, creating new opportunities for destinations to connect travelers with experiences that truly match their interests,” said Andy Moss, Co-founder and CEO of Mindtrip. “The Norwegian Travel Cluster’s decision to bring destination organizations together around a shared vision is a powerful example of how technology can amplify local expertise. Together, we’re helping travelers move from inspiration to action while discovering the diversity of Norway’s regions, communities, and experiences.”

Representing destinations from Lindesnes in the south to Svalbard in the High Arctic, the Norwegian Travel Cluster includes more than 150 municipalities, and thousands of tourism businesses focused on innovation, collaboration, and sustainable destination development. Building on this collective expertise, “Norway by Locals” will deliver personalized itineraries with curated recommendations, visuals, interactive maps, and guidance across accommodations, dining, attractions, transportation, and more. The platform is designed to guide visitors toward relevant local experiences, lesser-known places, and more responsible travel choices while making it easier to explore multiple regions in a single trip. Destination organizations will also help shape the experience by influencing which places, businesses, and themes are highlighted, ensuring recommendations reflect local priorities.

“Travel is evolving, and destinations need new ways to connect travelers with the experiences that matter most to them,” said Kristoffer Paulsen of the Norwegian Travel Cluster. “Norway by Locals is built on a simple idea: local knowledge creates better travel experiences. Together with Mindtrip, we’re making it easier for travelers to discover, plan, save, and share journeys across Norway while strengthening destination organizations, supporting local businesses, and inspiring visitors to explore beyond the familiar.”

The platform will also provide participating destination organizations with aggregated insights into what travelers are searching for, which places and experiences they explore, and what inspires them to take action. These insights will help inform destination development and future marketing efforts. Together, Norway by Locals creates a shared national entry point for travel planning that benefits visitors, local businesses, and destinations across Norway.

The partnership builds on Mindtrip’s expanding work with destination organizations worldwide that are adopting AI-powered travel discovery to better inspire and serve travelers. Current partners include national tourism organizations such as Brand USA, The Bahamas, Peru, and Visit Costa Rica; U.S. territories including Discover Puerto Rico; state tourism organizations such as Visit California, Travel Wyoming, and Travel Nevada; regional destinations including the Outer Banks Visitors Bureau and See Monterey; and city destinations including Visit Orlando, Visit Anaheim, New Orleans & Company, and Visit Truckee-Tahoe.

To learn more about Mindtrip for Business, visit mindtrip.ai/business.

About Mindtrip

Mindtrip is your personal travel assistant, one that knows you, works for you and keeps you one step ahead. Powered by agentic AI and travel-specific intelligence, Mindtrip learns what matters to you, remembers it from one trip to the next and helps you plan, book and navigate every stage of your journey with greater confidence. Mindtrip also powers AI experiences on destination, hotel and travel brand websites, helping partners deliver more personalized traveler experiences. Founded in 2023 in Silicon Valley by serial entrepreneurs with a proven track record of bringing innovative technology products to market, Mindtrip was built on the belief that travel should start with you, not just where you’re going. Learn more at Mindtrip.ai.

About Norwegian Travel Cluster

The Norwegian Travel Cluster is Norway’s national tourism cluster, dedicated to strengthening sustainable destination development through collaboration, innovation, and shared knowledge. Representing 29 destination marketing organizations (DMOs) and regions from Lindesnes to Svalbard, the Cluster supports a nationwide network of over 150 municipalities and thousands of tourism businesses. In 2026, it became the only tourism cluster accepted into Norwegian Innovation Clusters, and it develops shared tools, best practices, and collaborative solutions that help destinations create more sustainable and competitive visitor experiences.

Media Contact:
Rachel Rogers
3107704917
424647@email4pr.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/mindtrip-partners-with-norwegian-travel-cluster-to-power-ai-driven-discovery-across-norways-29-destination-regions-302908049.html

SOURCE Mindtrip

Continue Reading

Technology

Cogent Communications to Host Third Quarter 2026 Earnings Call on November 5, 2026

Published

39 minutes ago

on

October 14, 2026

By

WASHINGTON, Oct. 14, 2026 /PRNewswire/ — Cogent Communications Holdings, Inc. (“Cogent”) (NASDAQ: CCOI) will host a conference call at 8:30 a.m. (ET) on November 5, 2026 to present Cogent’s operating results for the third quarter of 2026 and answer questions. Cogent will issue a press release announcing the operating results at 7:00 a.m. (ET) on November 5, 2026.

Participation is open to all parties and this call may be accessed as follows:

Dial-in Numbers: 

1-833-461-5787 for U.S. callers

1-585-542-9983 for International callers

Conference ID 125652046

We recommend callers dial in 15 minutes prior to the start of the call to ensure you are connected.

Internet:

An audio webcast is accessible under “Events” in the “News” section of Cogent’s website at www.cogentco.com/events and will remain available through November 20, 2026. A printed transcript will be posted on the website when it becomes available.

About Cogent
Cogent (NASDAQ: CCOI) is a facilities-based provider of low cost, high speed Internet access and private network services to bandwidth intensive businesses. Cogent’s facilities-based, all-optical IP network provides services in 308 markets globally.

Cogent is headquartered at 2450 N Street, NW, Washington, D.C. 20037. For more information, visit www.cogentco.com. Cogent can be reached in the United States at (202) 295-4200 or via email at info@cogentco.com.

Information in this release may involve expectations, beliefs, plans, intentions or strategies regarding the future.These forward-looking statements involve risks and uncertainties.All forward-looking statements included in this release are based upon information available to Cogent Communications Holdings, Inc. as of the date of the release, and we assume no obligation to update any such forward-looking statement.The statements in this release are not guarantees of future performance and actual results could differ materially from our current expectations.Numerous factors could cause or contribute to such differences.Some of the factors and risks associated with our business are discussed in Cogent’s registration statements filed with the Securities and Exchange Commission and in its other reports filed from time to time with the SEC.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/cogent-communications-to-host-third-quarter-2026-earnings-call-on-november-5-2026-302908568.html

SOURCE Cogent Communications Holdings, Inc.

Continue Reading

Trending